Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$33.55 USD
+0.72 (2.19%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $33.78 +0.23 (0.69%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.55 USD
+0.72 (2.19%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $33.78 +0.23 (0.69%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Zacks News
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 600% and 0.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
HRMY or REGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?
Wall Street Analysts See a 32.82% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 32.8% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
5 High Earnings Yield Value Stocks That You Shouldn't Ignore
by Rimmi Singhi
Unlock your portfolio value by investing in stocks like HRMY, GPRK, GCT, CMRE and ARKO to fetch handsome returns.
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
by Zacks Equity Research
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
HRMY or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. TECH: Which Stock Is the Better Value Option?
HRMY vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. TECH: Which Stock Is the Better Value Option?
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -39.19% and 0.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
HRMY or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. ILMN: Which Stock Is the Better Value Option?
Wall Street Analysts Believe Harmony Biosciences Holdings, Inc. (HRMY) Could Rally 28.77%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Harmony Biosciences Holdings, Inc. (HRMY) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HRMY vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Bears are Losing Control Over Harmony Biosciences Holdings, Inc. (HRMY), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Does Harmony Biosciences Holdings, Inc. (HRMY) Have the Potential to Rally 32.19% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 32.2% in Harmony Biosciences Holdings, Inc. (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Harmony Biosciences Holdings, Inc. (HRMY) Rating Upgrade to Buy
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HRMY or ACAD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. ACAD: Which Stock Is the Better Value Option?
HRMY or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. GMAB: Which Stock Is the Better Value Option?
Wall Street Analysts Predict a 44.38% Upside in Harmony Biosciences Holdings, Inc. (HRMY): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Harmony Biosciences Holdings, Inc. (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HRMY vs. REGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?
How Much Upside is Left in Harmony Biosciences Holdings, Inc. (HRMY)? Wall Street Analysts Think 76.62%
by Zacks Equity Research
The mean of analysts' price targets for Harmony Biosciences Holdings, Inc. (HRMY) points to a 76.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?